Similar articles

• Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial.

  Granton J, Langleben D, Kutryk MB, Camack N, Galipeau J, Courtman DW, Stewart DJ. Granton J, et al. Circ Res. 2015 Sep 11;117(7):645-54. doi: 10.1161/CIRCRESAHA.114.305951. Epub 2015 Jul 20. Circ Res. 2015. PMID: 26195220 Clinical Trial.
• Gene therapy techniques for the delivery of endothelial nitric oxide synthase to the lung for pulmonary hypertension.

  Deng W, Bivalacqua TJ, Champion HC, Hellstrom WJ, Murthy SN, Kadowitz PJ. Deng W, et al. Methods Mol Biol. 2010;610:309-21. doi: 10.1007/978-1-60327-029-8_18. Methods Mol Biol. 2010. PMID: 20013186
• Therapeutic effect of eNOS-transfected endothelial progenitor cells on hemodynamic pulmonary arterial hypertension.

  Wei L, Zhu W, Xia L, Yang Y, Liu H, Shen J, Zhu J, Xu Y, Yang Z, Wang C. Wei L, et al. Hypertens Res. 2013 May;36(5):414-21. doi: 10.1038/hr.2012.217. Epub 2013 Feb 28. Hypertens Res. 2013. PMID: 23446773
• Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials.

  Jurasz P, Courtman D, Babaie S, Stewart DJ. Jurasz P, et al. Pharmacol Ther. 2010 Apr;126(1):1-8. doi: 10.1016/j.pharmthera.2009.12.006. Epub 2010 Feb 1. Pharmacol Ther. 2010. PMID: 20117135 Review.
• Pulmonary arterial hypertension: on the way to a manageable disease.

  Mucke HA. Mucke HA. Curr Opin Investig Drugs. 2008 Sep;9(9):957-62. Curr Opin Investig Drugs. 2008. PMID: 18729002 Review.